Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis - PubMed

Recent guidelines in British Columbia, Canada have suggested that the use of a maximum of 3 monthly doses of palivizumab 15 mg/kg intramuscularly for RSV immunoprophylaxis of high risk infants born prior to the RSV season is adequate to provide protection against severe RSV disease for a 5-month RSVā€¦